Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study

ObjectiveCamrelizumab, a programmed death-1 inhibitor, is effective and safe for treating patients with advanced lung cancer according to previous phase 3 trials. However, relevant real-world clinical evidence is required. This study intended to explore the efficacy and safety of camrelizumab-based...

Full description

Bibliographic Details
Main Authors: Dong Zhao, Minghong Bi, Xiaofei Cheng, Shuhong Wang, Huaidong Cheng, Xiaoyang Xia, Huan Chen, Yanbei Zhang, Zhiqiang Hu, Qisheng Cao, Hui Liang, Fan Wang, Xuhong Min, Ling Xu, Kehai Feng, Jinhua Zhou, Xinzhong Li, Rui Wang, Hua Xie, Xiaosi Chen, Kangsheng Gu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
advanced lung cancer
camrelizumab-based therapies
treatment response
survival
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1494708/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1494708/full

Similar Items